Addlife har en solid position inom en bransch med stabil och ökande efterfrågan.
Redeye has updated its estimates for Safeture following the Q2 2024 report, which was in line with o...
Redeye is hoping for a swift and robust solution to OXE Marine’s financial predicament.
Net sales and clean EBIT were in line with consensus but the share price declined by 7.
Redeye ger en kort kommentar om det negativa utlåtandet från CHMP.
Redeye comments on EG7’s announcement of preliminary Q2-results which are below our expectations.
- Profitability yet to improve - Extrem Borr och Sågteknik added to numbers - Positive revision main...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 25 juli år 2024 a...
Net sales and adjusted EBIT were close to market consensus (LSEG) in Q2.
Vaisala’s Q2 was strong with solid volume growth, favorable sales mix in IM and continued OPEX disci...
Redeye comments on Sleep Cycle's Q2 2024 report, which came in slightly better on sales and EBIT tha...
- Earnings up y-o-y, but still undershot our estimates in Q2 - Profitability issues should be mainly...
- Q2 sales EUR 43m, -7% y-o-y, order intake EUR 40m, +11% y-o-y - Minor adjustments to '24-'26 estim...
- Optimism running high after another solid quarter - Positive long-term revisions, '26e EBIT up 1% ...
Kvartalet belastades av en svagare konjunktur och lägre volymer för Hanzas kunder.
Vaisala’s delivered very strong figures for Q2/24 as our estimates were topped on both net sales and...
- Orders -6% vs ABGSCe, sales in line, EBIT 31% above - Adj.
- '24e-'25e EBITA down 2-3% - Capacity investments to aid organic growth - '25e lease adj.
Underliggande portföljbolagen utvecklas väl även om försäljningen av Gett och en viss multipelnedgån...
Redeye briefly comments on Mendus announcing a collaboration with Institut Bergonié that involves tr...
